Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:19 September 2023

SPEAR: This study is assessing how well an anti-inflammatory drug prevents cancer growth in people with advanced or metastatic pancreatic cancerA phase 2, open-label, single-arm sulfasalazine monotherapy trial of progression-free survival in patients with pancreatic adenocarcinoma

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

Participants will commence treatment with sulfasalazine (500mg oral tablets) at 1.5g per day in three evenly divided doses. The dose will be increased in stages to the target dose of 4.5g per day. The dose may be further increased to 6g per day if there are no significant intolerances and with researcher approval. How quickly the doses are increased will depend on each participant's acetylator status, which affects how quickly sulfasalazine is processed in the body.

Age

People 18+

Phase

Trial Acronym

SPEAR

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

ACTRN12621001347853

Commercial Sponsor

Australian Genomic Cancer Medicine Centre Ltd t/a Omico

Scientific Title

A phase 2, open-label, single-arm sulfasalazine monotherapy trial of progression-free survival in patients with pancreatic adenocarcinoma

Share with email

Print this page

Download brochure

Eligibility

Inclusion

You have certain types of non-cancer medical conditions.
You have been diagnosed with a prior or secondary type of cancer.
You have had certain treatments, surgical procedures or drugs.
You have previously been treated (or are currently being treated) on a clinical trial.

Exclusion

You are able to swallow medication by mouth.
You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Your cancer has not spread to other parts of the body.
Your cancer has spread to other parts of the body.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

+ Show non-recruiting hospitals

Not yet recruiting hospitals

Information Tell us if you find this trial availability is not accurate.Report inaccuracy